Co-delivery of NS1 and BMP2 mRNAs to murine pluripotent stem cells leads to enhanced BMP-2 expression and osteogenic differentiation
Source abstract
Abstract
Application of messenger RNA (mRNA) for bone regeneration is a promising alternative to DNA, recombinant proteins and peptides. However, exogenous in vitro transcribed mRNA (IVT mRNA) triggers innate immune response resulting in mRNA degradation and translation inhibition. Inspired by the ability of viral immune evasion proteins to inhibit host cell responses against viral RNA, we applied non-structural protein-1 (NS1) from Influenza A virus (A/Texas/36/1991) as an IVT mRNA enhancer. We evidenced a dose-dependent blocking of RNA sensors by NS1 expression. The co-delivery of NS1 mRNA with mRNA of reporter genes significantly increased the translation efficiency. Interestingly, unlike the use of nucleosides modification, NS1-mediated mRNA translation enhancement does not dependent to cell type. Dual delivery of NS1 mRNA and BMP-2 mRNA to murine pluripotent stem cells (C3H10T1/2), promoted osteogenic differentiation evidenced by enhanced expression of osteoblastic markers (e.g. alkaline phosphatase, type I collagen, osteopontin, and osteocalcin), and extracellular mineralization. Overall, these results support the adjuvant potentiality of NS1 for mRNA-based regenerative therapies. STATEMENT OF SIGNIFICANCE: mRNA therapy has the potential to improve the efficiency of nucleic acid based regenerative medicine. Up to now, the incorporation of expensive modified nucleotides is a common way to avoid IVT mRNA-induced detrimental immunogenicity. We here introduce co-delivery of Influenza virus immune evasion protein-NS1 coding mRNA as a strategy to suppress RNA sensors for maximizing IVT mRNA expression. An increased osteogenic commitment of pluripotent stem cells was observed after BMP2 mRNA and NS1 mRNA delivery. This study revealed how applying non-modified mRNA with NS1 could be a promising alternative as a therapeutic in bone regeneration.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Virus-based gene therapy research · RNA Interference and Gene Delivery · RNA Research and Splicing
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (57)
Show source-provided references
1. Bone physiology as inspiration for tissue regenerative therapies10.1016/j.biomaterials.2018.09.028 ↗
2. Porous nano-HA/collagen/PLLA scaffold containing chitosan microspheres for controlled delivery of synthetic peptide derived from BMP-210.1016/j.jconrel.2008.11.020 ↗
3. Enhanced angiogenesis and osteogenesis in critical bone defects by the controlled release of BMP-2 and VEGF: implantation of electron beam melting-fabricated porous Ti6Al4V scaffolds incorporating growth factor-doped fibrin glue10.1088/1748-6041/10/3/035013 ↗
4. Spinal reconstruction and bone morphogenetic proteins: open questions10.1016/S0020-1383(09)70009-9 ↗
5. RNA-based therapy for osteogenesis10.1016/j.ijpharm.2019.118594 ↗
6. Gene therapy approaches to regenerating the musculoskeletal system10.1038/nrrheum.2015.28 ↗
7. Enhancement of bone regeneration by gene delivery of BMP2/Runx2 bicistronic vector into adipose-derived stromal cells10.1016/j.biomaterials.2010.03.019 ↗
8. Delivery of the improved BMP-2-Advanced plasmid dna within a gene-activated scaffold accelerates mesenchymal stem cell osteogenesis and critical size defect repair10.1016/j.jconrel.2018.05.022 ↗
9. Adeno-associated virus vector as a platform for gene therapy delivery10.1038/s41573-019-0012-9 ↗
10. 828. Optimizing the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) for safety and function in Lentiviral vectors
11. Coordinating cell proliferation and differentiation: antagonism between cell cycle regulators and cell type-specific gene expression10.1080/15384101.2015.1120925 ↗
12. Vaccination with messenger RNA (mRNA)10.1007/978-3-540-72167-3_11 ↗
13. mRNA as novel technology for passive immunotherapy
14. Suppression of rna recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA10.1016/j.immuni.2005.06.008 ↗
15. Recognition of double-stranded RNA and activation of NF-KAPPAB by toll-like receptor 310.1038/35099560 ↗
16. Species-specific recognition of single-stranded rna via toll-like receptor 7 and 810.1126/science.1093620 ↗
17. mRNA is an endogenous ligand for toll-like receptor 310.1074/jbc.M310175200 ↗
18. Induction and activation of antiviral enzyme 2′,5′-oligoadenylate synthetase by in vitro transcribed insulin mRNA and other cellular RNAs10.1007/s11033-012-1624-x ↗
19. Screening of mRNA chemical modification to maximize protein expression with reduced immunogenicity10.3390/pharmaceutics7030137 ↗
20. Non-linear enhancement of mRNA delivery efficiencies by influenza a derived NS1 protein engendering host gene inhibition property10.1016/j.biomaterials.2017.04.009 ↗
21. Messenger rna translation enhancement by immune evasion proteins: a comparative study between ekb (vaccinia virus) and NS1 (influenza a virus)10.1038/s41598-019-48559-6 ↗
22. Viral mechanisms of immune evasion10.1016/S0167-5699(00)01699-6 ↗
23. Viruses and interferon: a fight for supremacy10.1038/nri888 ↗
24. Evading innate immunity in nonviral mRNA delivery: don't shoot the messenger10.1016/j.drudis.2015.07.009 ↗
25. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN10.1128/JVI.74.23.11230-11239.2000 ↗
26. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA10.1016/j.stem.2010.08.012 ↗
27. Efficient generation of human iPSCs by a synthetic self-replicative RNA10.1016/j.stem.2013.06.001 ↗
28. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction10.1038/nbt.2682 ↗
29. The multifunctional NS1 protein of influenza a viruses10.1099/vir.0.2008/004606-0 ↗
30. The primary function of rna binding by the influenza a virus NS1 protein in infected cells: inhibiting the 2′-5′ oligo (A) synthetase/RNase l pathway10.1073/pnas.0602184103 ↗
31. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action10.1128/MMBR.00027-06 ↗
32. Influenza a virus NS1 protein prevents activation of NF-KAPPAB and induction of alpha/beta interferon10.1128/JVI.74.24.11566-11573.2000 ↗
33. Activation of interferon regulatory factor 3 is inhibited by the influenza a virus NS1 protein10.1128/JVI.74.17.7989-7996.2000 ↗
34. Effects of chemically modified messenger RNA on protein expression10.1021/acs.bioconjchem.6b00090 ↗
35. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA, nanomedicine: nanotechnology
36. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules10.4049/jimmunol.158.6.2723 ↗
37. An assay for the determination of biologically active bone morphogenetic proteins using cells transfected with an inhibitor of differentiation promoter-luciferase construct10.1016/j.ab.2005.10.030 ↗
38. Messenger RNA-based therapeutics for brain diseases: an animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles10.1016/j.jconrel.2016.06.001 ↗
39. Simultaneous delivery of hydrophobic small molecules and siRNA using sterosomes to direct mesenchymal stem cell differentiation for bone repair10.1016/j.actbio.2017.05.057 ↗
40. Chemically modified rna activated matrices enhance bone regeneration10.1016/j.jconrel.2015.09.050 ↗
41. Chemically modified rna induces osteogenesis of stem cells and human tissue explants as well as accelerates bone healing in rats10.1016/j.biomaterials.2016.02.018 ↗
42. An improved, chemically modified RNA encoding BMP-2 enhances osteogenesis in vitro and in vivo
43. Control of mammalian translation by mRNA structure near caps10.1261/rna.2309906 ↗
44. Modification of antigen-encoding rna increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells10.1182/blood-2006-04-015024 ↗
45. mRNA transfection of dendritic cells: synergistic effect of arca mRNA capping with poly(a) chains in cis and in trans for a high protein expression level10.1016/j.bbrc.2005.12.105 ↗
46. pEVL: a linear plasmid for generating mRNA ivt templates with extended encoded poly(a) sequences10.1038/mtna.2016.21 ↗
47. Influenza a virus NS1 induces G0/G1 cell cycle arrest by inhibiting the expression and activity of rhoa protein10.1128/JVI.03176-12 ↗
48. Why, when and how does the poly (A) tail shorten during mRNA translation?10.1016/0020-711X(93)90615-L ↗
49. Eukaryotic mRNA decapping10.1146/annurev.biochem.73.011303.074032 ↗
50. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability10.1038/mt.2008.200 ↗
51. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals10.1038/mt.2015.103 ↗
52. Optimizing cardiac delivery of modified mRNA10.1016/j.ymthe.2017.03.016 ↗
53. A CBFA1-dependent genetic pathway controls bone formation beyond embryonic development10.1101/gad.13.8.1025 ↗
54. Characterization of mesenchymal stem cells derived from rat bone marrow and adipose tissue: a comparative study10.15283/ijsc.2014.7.2.135 ↗
55. BMP responsiveness in human mesenchymal stem cells10.1080/03008200390181825 ↗
56. A.M. Osyczka, D.L. Diefenderfer, G. Bhargave, P.S. Leboy, Different effects of BMP-2 on marrow stromal cells from human and rat bone, cells, tissues, organs176(1–3) (2004) 109–19.10.1159/000075032 ↗
57. A comparative study of the bone regenerative effect of chemically modified RNA encoding BMP-2 or BMP-910.1208/s12248-016-0034-8 ↗